Strategic exit momentum Gilgamesh Pharma recently completed a significant asset sale to AbbVie valued at up to 1.2 billion, signaling a strong exit momentum and potential for collaboration on high-value neuroscience assets with large pharma buyers.

Clinical stage leverage As a clinical-stage neuroscience company developing rapid-acting and durable therapies, Gilgamesh presents opportunities for early engagement around strategically partnered trials, licensing of GM-3009 derivatives, and co-development deals for PTSD, MDD and substance use disorder programs.

Pipeline vitality Active development of ibogaine derivatives and ketamine-related programs with a focus on safety, cardiac risk reduction, and PTSD indicates a diversified pipeline ripe for partnerships, strategic investments, or acquisition conversations to bolster psych-neuro portfolios.

Financial capability With a Series A of 60 million and a total funding footprint of approximately 149 million alongside demonstrated revenue and growth potential, Gilgamesh has the financial runway to pursue co-development, milestone-based deals, and pragmatic out-licensing strategies.

Regulatory readiness Recent leadership hires in regulatory affairs and active engagement with regulatory partners position Gilgamesh for accelerated pathways, suggesting BD plays well with teams offering regulatory strategy, filings support, and market access expertise to de-risk partnerships.